Isis drug to be tested in amyotrophic lateral sclerosis
Based on findings in rats, researchers believe this drug has the potential to be an effective treatment for inherited amyotrophic lateral sclerosis (ALS, also called Lou Gehrig’s disease).
The US Food and Drug Administration (FDA) is set to review Kowa Pharmaceuticals America’s new drug application (NDA) for K-911, an investigational once-daily eye drop aimed at reducing intraocular pressure (IOP) in open-angle glaucoma (OAG) or ocular hypertension (OHT) patients.